BERLIN, Jan 27 (Reuters) - Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor being developed to treat obesity, delivered positive results.
Advertisement
(Writing by Miranda Murray)
